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Objective. To assess the effect of vitamin D supplementation on neuropathy specific quality of life (NeuroQoL) in patients with
painful diabetic neuropathy. Methods. This prospective, open label study was conducted between June 2012 and April 2013.
Patients with symptomatic diabetic neuropathy were given a single dose of 600,000 IU intramuscular vitamin D, and NeuroQol
was assessed at baseline and at five follow-up visits every 4 weeks. Results. Of 143 participants, 41.3% were vitamin D deficient
(vitamin D< 20 ng/ml). Treatment with vitamin D resulted in a significant increase in 25(OH)D (P < 0 0001) and a significant
improvement in the NeuroQoL subscale score for emotional distress (P = 0 04), with no significant change in the other
NeuroQoL domains of painful symptoms and paresthesia, loss of temperature and touch sensation, unsteadiness, limitation in
daily activities, and interpersonal problems. There was a significant reduction in patient perception about foot problems on QoL
of “quite a lot” (P < 0 05) and “very much” (P < 0 0001) with a significant reduction in the baseline response of having a “poor”
QoL from 5.2% to 0.7% (P < 0 0001) and an increase in the response of an “excellent QoL” from 1.5% to 7.4% (P < 0 0001).
Conclusion. Vitamin D is effective in improving quality of life in patients with painful diabetic neuropathy.
1. Introduction
Painful diabetic neuropathy is a major complication of dia-
betes, characterised by pain, tingling, burning, and cramps
in the feet and lower legs with a significant reduction in
quality of life [1]. In our previous large population-based
study in the UK, the prevalence of painful diabetic neurop-
athy was 21% in Europeans but 34% in South Asians [2].
The prevalence of painful diabetic neuropathy ranges from
50% in Turkey [3], 22–60% in the Middle East [4], and 69%
in Pakistan [5]. These differences have been attributed to
different populations from primary and secondary care,
criteria for diagnosing painful neuropathy, and different
patient demographics.
Vitamin D deficiency is more prevalent in South
Asians [6], even in people living in South Asia including
Pakistan [7], and in Pakistan, the prevalence of vitamin
D deficiency ranges from 40% [8] to 83% [9]. Vitamin D
deficiency itself has been associated particularly with diabetic
peripheral neuropathy [10–12] rather than retinopathy or
maculopathy [13, 14]. In a study conducted in Kuwait,
vitamin D deficiency occurred in ~82% of patients with
diabetic neuropathy compared to ~61% of patients without
neuropathy (P < 0 05) [15]. A meta-analysis has confirmed
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this association and showed an odds ratio of ~2.9 (95% CI
1.84–4.50) in favour of diabetic neuropathy in patients with
vitamin D deficiency [16]. Recently in China, vitamin D defi-
ciency has also been shown to be an independent risk factor
for diabetic peripheral neuropathy [17]. We have recently
shown a significant reduction in the severity of painful dia-
betic neuropathy after treatment with vitamin D [18].
Patients with diabetes have a worse quality of life (QoL)
compared to persons without diabetes [19], especially those
with diabetic neuropathy [20]. Painful neuropathy reduces
quality of life (QoL) which appears to be mediated through
increased anxiety, depression, physical burden, emotional
disorders, and limitation of mobility. Relief of neuropathic
pain with pharmacological agents has been shown to
improve QoL [21–23].
The current study assessed the effect of treatment with a
single intramuscular injection of high dose vitamin D on
quality of life in patients with painful diabetic neuropathy
using the NeuroQoL questionnaire (a specific validated
neuropathy QoL instrument).
2. Methods
This was a prospective, open label clinical trial in patients
with painful diabetic neuropathy between June 2012 and
April 2013 undertaken in the Baqai Institute of Diabetology
and Endocrinology (BIDE), a tertiary care diabetes unit in
Karachi, Pakistan. The study received ethics approval from
the institutional review board (IRB) of BIDE. Study partici-
pants gave signed informed consent in keeping with the
Declaration of Helsinki.
Patients with symptomatic diabetic neuropathy aged
above 18 years and HbA1c≤ 11% with no comorbidities were
included in the study after obtaining informed consent. None
of the patients were actively receiving vitamin D supplemen-
tation during recruitment. Participants received a single dose
of intramuscular vitamin D₃ of 600,000 IU and were assessed
at five follow-up visits every 4 weeks.
Height, weight (ZT-160 scales, WINCOM, Jiangsu,
China), and blood pressure was assessed, and body mass
index was calculated using the formula (weight in kg/height
in m2).
The laboratory used internal quality controls for the
measurement of 25(OH)D. Serum 25(OH)D was measured
using the immunoenzymetric assay, based on a solid phase
enzyme-linked immunosorbent assay (ELISA) performed
on microtiter plates and was performed exactly as per the
manufacturer’s instructions. The cross reactivity for vitamin
D2 (of the assay) as per manufacturer’s assertion was 100%
(relative to vitamin D3), and the assay has excellent correla-
tion to existing globally recognized assays, in combination
with good sensitivity and precision (EP17-A Protocols for
Determination of Limits of Detection and Limits of Quanti-
tation; approved guideline, standard published by Clinical
and Laboratory Standards Institute). The linear range of the
assay is 7.7 ng/ml to 122.9 ng/ml. Inter- and intra-assay vari-
ation of the in-house control was 2.5% and 9.2%, respectively.
Deficiency was defined as a 25(OH)D< 20 ng/ml, insuffi-
ciency as 25(OH)D values 20–30ng/ml, and adequacy as a
25(OH)D≥ 30 ng/ml. These cutoffs are based on the Endo-
crine Society Clinical Practice Guideline, 2011.
3. Neuropathy Specific Quality of Life
Questionnaire (NeuroQol)
The NeuroQoL is a specific validated neuropathy and foot
ulcer QoL instrument [24, 25] which assesses diabetic
neuropathy-related physical and emotional problems affect-
ing daily life and well-being. Each question has a Likert scale
of 1 to 5 for frequency of symptoms where 1 represents
“never” and 5 represents “all the time.” 27 questions were
divided into six subscales, that is, painful symptoms and
paresthesia; reduction or loss of ability to feel temperature
and/or objects with the feet; unsteadiness while standing/
walking; limitation in daily activities; interpersonal problems,
for example, physical/emotional dependence on others;
and emotional distress. Six questions are related to the
patient’s perception of symptoms affecting QoL, and two
separate questions assess the overall impact of neuropathy
on QoL [24].
4. Statistical Analysis
All demographic, biochemical, and NeuroQol data were
analysed using StatsDirect, Cheshire, UK. The data are
presented as mean± standard deviation (SD) and median
with interquartile range where appropriate. All participants
enrolled into the study were included in the analyses with
missing data handled by using the Last Observation Carried
Table 1: Baseline characteristics of patients.
Baseline characteristics Total
n 143
Age (years) 52.3± 11.50
Male gender, n (%) 59 (41%)
Type 1 7 (4.9%)
Type 2 136 (95.1%)
Duration of diabetes (years) 12.1± 7.60
Body mass index (kg/m2) 29.7± 5.8
Systolic BP (mm/Hg) 126± 16
Diastolic BP (mm/Hg) 80± 9
Serum creatinine (mg/dl) 0.98± 0.30
Calcium (mg/dl) 8.7± 0.6
Serum cholesterol (mg/dl) 169± 41
Triglyceride (mg/dl) 134± 80
High-density lipoprotein (mg/dl) 39± 10
Low-density lipoprotein (mg/dl) 106± 34
HbA1c (%) 8.6± 1.5
HbA1c (mmol/mol) 70.2± 16.4
25(OH)D (ng/ml) 31.7± 23.2
Deficient (<20 ng/ml) 58 (40.6%)
Insufficient (20–30 ng/ml) 24 (16.8%)
Sufficient (>30 ng/ml) 61 (42.7%)
Data are presented as n (%) or mean ± SD.
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Forward (LOCF). Student’s t-test or nonparametric counter-
part and chi-square test were used for analysis of anthropo-
metric, metabolic parameters and patient’s perception and
general classification of QoL (Table 1, Figures 1(a) and
1(b)). The nonparametric Kruskall-Walis test was utilized
with post hoc analyses (Conover-Iman) to test differences
in NeuroQoL subscale scores from visit 1 to visit 5. Appro-
priate statistical tests were employed for both parametric and
nonparametric data. Overall P value for multiple comparison
tests were kept at 0.05. A P value of ≤0.05 was considered
statistically significant.
5. Results
Table 2 summarises the anthropometric and demographic
characteristics of the participants. 41% were males, 4.9%
had type 1 diabetes, and 95.1% had type 2 diabetes.
The age of participants was 52.3± 11.5 years, duration
of diabetes was 12.1± 7.6 years, body mass index (BMI)
was 29.7± 5.8 kg/m2, and HbA1c was 70.2± 16.4mmol/mol.
40% had vitamin D deficiency (vitamin D< 20 ng/ml), 17%
had insufficiency (vitamin D 20–30 ng/ml), and 43% had
sufficient (vitamin D> 30ng/ml) levels. There were no differ-
ences in anthropometric, clinical, and biochemical variables
between patients with deficient, insufficient, and sufficient
levels of vitamin D.
6. Effect of Treatment with Vitamin D (Table 1)
Treatment with vitamin D resulted in a significant increase
in 25(OH)D (P < 0 0001), calcium (P = 0 009), and HDL
(P = 0 03) and a reduction in HbA1c (P = 0 02) (Table 1).
There was a significant improvement in the NeuroQoL
subscale score for emotional distress by visit 3 (P = 0 04)
which was maintained to the end of the study (Table 3).
There were no significant changes in the other NeuroQoL
domains of painful symptoms and paresthesia, loss of
temperature and touch sensation, unsteadiness, limitation
in daily activities, interpersonal problems, reduced QoL,
and total QoL (Table 3).
After stratification of participants into those with suffi-
cient (≥30ng/ml, n = 80) and deficient (<30 ng/ml, n = 63)
levels of vitamin D at baseline, we assessed the response to
vitamin D in the NeuroQoL subscale for emotional distress
(Table 4). Emotional distress improved significantly only in
subjects with a vitamin D< 30 ng/ml (P = 0 04), whilst those
with a baseline vitamin D status≥30ng/ml showed no signif-
icant change (Table 4). There was no change in any other
domain from visit 1 to visit 5 when stratifying subjects based
on sufficient (≥30 ng/ml) and deficient (<30ng/ml) levels of
vitamin D at baseline. There was also no correlation of base-
line vitamin D with individual domains of the NeuroQoL
using Kendall’s rank correlation.
There was a significant reduction in the patient responses
of “quite a lot” (P < 0 05) and “very much” (P < 0 0001) on
patient perception about foot problem effect on QoL
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Figure 1: (a) Comparison of baseline and posttreatment patient’s perception on QoL. (b) Comparison of baseline and post treatment general
classification on QoL. ∗P < 0 05, ∗∗P < 0 0001.
Table 2: Baseline and end of trial anthropometric and metabolic
parameters after administration of vitamin D.
Parameters (n = 143) Baseline Week 20 P value
Body mass index (kg/m2) 29.7± 5.8 30.2± 7.1 NS
Systolic BP (mmHg) 126± 16 123± 15 NS
Diastolic BP (mmHg) 80± 9 78± 7 NS
HbA1c (%) 8.6± 1.5 8.2± 1.5
0.02
HbA1c (mmol/mol) 70.2± 16.4 66.1± 16.6
Creatinine (mg/dl) 0.98± 0.3 1.01± 0.4 NS
Calcium (mg/dl) 8.7± 0.6 8.9± 1.0 0.009
Serum cholesterol (mg/dl) 169± 41 162± 43 NS
Triglycerides (mg/dl) 134± 80 136± 78 NS
High-density lipoprotein
(mg/dl)
39± 10 43± 11 0.03
Low-density lipoprotein
(mg/dl)
106± 34 100± 34 NS
25(OH)D (ng/ml) 31.7± 23.2 46.2± 10.2 <0.0001
Data are presented as mean ± SD.
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(Figure 1(a)). There was a significant reduction in the base-
line response of having a “poor” QoL from 5.2% to 0.7%
(P < 0 0001) and an increase in the response of an “excel-
lent QoL” from 1.5% to 7.4% (P < 0 0001) (Figure 1(b)).
7. Loss to Follow-Up
Seven participants did not complete at visit 5, two partic-
ipants at visit 4, one participant at visit 3, and one
participant at visit 2. All participants enrolled into the
study were included in subsequent analyses with LOCF for
NeuroQol analyses.
8. Discussion
Diabetes and painful diabetic neuropathy are associated
with reduced quality of life [20, 26–28]. Indeed, in a
recent study the Norfolk, Qol-DN score was administered
to 21,261 patients and demonstrated a 3-fold reduction in
QoL in those with diabetic neuropathy [29]. Neuro-QoL
is a validated tool for assessing neuropathy specific qual-
ity of life (QoL) in patients with diabetes [24] and has
been employed to show an association between diabetic
neuropathy and depressive symptoms [30]. The main
findings of this study are that administration of a single
high-dose treatment with vitamin D showed a significant
improvement in specific NeuroQol subscale of emotional
distress, improvements in the self-classification of QoL
with fewer subjects classifying their QoL as poor, and
“foot problems” causing less perceived reduced QoL.
Pharmacological interventions for painful diabetic neurop-
athy may [28, 31] or may not [32] show an improvement
in QoL due to significant side effects. Interestingly, a recent
analysis of the COMBO-DN study has shown that treat-
ment with duloxetine was of most benefit in patients with-
out low mood [33].
A previous study has shown an improvement in pain,
sleep, and quality of life after treatment with vitamin D in
subjects with chronic pain [34]. We and others have demon-
strated an improvement in pain-related symptom scores in
diabetic patients with painful neuropathy after treatment
with vitamin D [18, 35]. NeuroQoL is a neuropathy-specific
QoL tool for the assessment and follow-up of therapeutic
interventions in clinical trials of painful diabetic neuropathy.
The SF-12 questionnaire has shown a profound effect on
the physical and mental components of QoL in diabetic
Table 3: NeuroQoL measures from baseline to final visit.
NeuroQoL measures Baseline V2 V3 V4 V5
Pain 11.7± 4.1 11.3± 4.7 11.5± 4.4 11.3± 4.3 11.4± 3.9
(−/35) 11 (9–14) 10 (8–13) 10 (8–14) 10 (8–14) 11 (9–13)
Loss reduction 4.9± 2.4 4.8± 2.4 4.8± 2.6 4.7± 2.6 4.6± 2.2
(−/15) 4 (3–6) 4 (3–6) 4 (3–6) 4 (3–6) 4 (3–5)
Diffuse sensory-motor symptoms 6.1± 3.6 6.1± 3.6 6.1± 3.5 6.1± 3.4 6.5± 3.0
(−/15) 5 (3–7) 5 (3–8) 5 (3–7) 5 (3–7) 6 (4–8)
Limitations 4.5± 2.5 4.6± 2.5 4.2± 1.9 4.2± 2.0 4.1± 2.0
(−/15) 3 (3–5) 3 (3–6) 3 (3–5) 3 (3–5) 3 (3–5)
Interpersonal 6.3± 3.9 6.3± 4.1 5.6± 3.1 5.9± 3.5 5.6± 3.1
(−/20) 4 (4–7) 4 (4–7) 4 (4–7) 4 (4–7) 4 (4–7)
Emotional distress 13.4± 8.1 12.1± 7.5 11.0± 6.4 11.0± 6.0 10.8± 5.4
(−/35) 9 (7–20) 7 (7–17) 7 (7–13)∗ 7 (7–14)∗ 7 (7–15)∗∗
R QoL 12.0± 6.3 11.4± 6.2 11.2± 5.4 11.5± 5.2 11.2± 4.7
(−/30) 10 (7–16) 9 (7–15) 9 (7–14) 10 (7–14) 10 (8–13)
Total QoL 64.7± 24.3 62.3± 24.9 60.1± 21.8 60.2± 21.7 59.8± 18.2
(−/135) 57 (45–78) 54 (44–71) 53 (44–70) 54 (43–71) 55 (45–70)
Data are presented as mean ± SD and median (IQR). ∗P = 0 02 and ∗∗P = 0 03.
Table 4: Response in emotional distress stratified according to baseline vitamin D status (<30 ng/ml and ≥30 ng/ml).
NeuroQoL measures Baseline V2 V3 V4 V5
Emotional distress
25(OH)D< 30 ng/ml 13.5± 8.2 11.9± 7.7 10.7± 6.4 10.3± 5.3 10.4± 5.4
n = 80 (−/35) 8.5 (7–21) 7 (7–16) 7 (7–11) 7 (7–11.5)∗ 7 (7–14)∗
Emotional distress
25(OH)D≥ 30 ng/ml 13.4± 8.1 12.3± 7.2 11.4± 6.5 11.8± 6.8 11.3± 5.4
n = 63 (−/35) 10 (7–20) 7 (7–18) 7 (7–15) 7 (7–16) 7 (7–15)
Data are presented as mean ± SD and median (IQR), ∗P = 0 04.
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neuropathy [36]. However, the NeuroQoL physical symp-
tom and psychosocial functioning scales shows stronger
associations than the SF-12 with the clinical indicators of
neuropathic severity, by mediating more fully the relation-
ship of neuropathy to overall quality of life and explaining
additional variance beyond that accounted for by the SF-12
measures [24].
In the present study, treatment with vitamin D resulted in
an improvement in emotional distress after ~12 weeks, espe-
cially in those with low levels of vitamin D, suggesting a
biological basis for this response [37]. Furthermore, patient
perception of the general and more specific effect of foot
problems on QoL was improved, suggesting that even small
improvements in objective measures of neuropathic pain
may improve QoL. Of course, even modest improvements
in pain can produce clinically meaningful changes in
function and status [38]. Whilst we [16] and others [26]
have previously shown an improvement in the severity
of painful neuropathic symptoms, in the present study,
the subscale for positive and negative symptoms did not
change, possibly because they evaluated the frequency
rather than severity of these symptoms. Indeed, in a
recent placebo-controlled study, treatment with vitamin
D was associated with an improvement in positive neuro-
pathic symptoms with no effect on neuropathic deficits or
nerve conduction [10]. In relation to a lack of benefit on
unsteadiness, we have recently shown no association between
vitamin D deficiency and lower limb muscle strength or
volume [39].
Increasing evidence suggests that an adequate intake of
vitamin D should be encouraged particularly in populations
at risk of vitamin D deficiency [10–12]. In the present study,
we have shown an improvement in vitamin D levels as
well as HbA1c and HDL [40], with an impact on neuropathy
specific QoL.
This is an open label intervention study in a population
attending a secondary care setting and therefore cannot be
generalised to the whole diabetic population. We also cannot
exclude a placebo response particularly as subjects received
regular follow-up after a known active intervention, although
the improvement was observed several weeks after treatment
had commenced. We believe that the data warrant a larger
double-blind placebo-controlled clinical trial with vitamin
D to assess the benefits on painful neuropathic symptoms
and QoL.
9. Conclusion
A significantly improved neuropathy-specific quality of
life is observed following a single high-dose intramuscu-
lar treatment with vitamin D3 in patients with painful
diabetic neuropathy, particularly those with vitamin D
deficiency.
Additional Points
Key Message. Vitamin D may play an important role in
the treatment of painful diabetic neuropathy in relation
to quality of life. A single high-dose intramuscular
injection of vitamin D3 provides significant improvements
in neuropathy-specific aspects of the quality of life in
patients with diabetic neuropathy. Research Questions.
Are the quality of life improvements maintained over a
longer period time? Through which central mechanism(s)
does vitamin D cause improvement in quality of life? Are
the same findings replicated in a randomised placebo con-
trolled trial? Guarantor of Data and Manuscript. Asher Faw-
wad is the guarantor of this work and, as such, had full access
to all the data in the study and takes responsibility for the
integrity of the data and the accuracy of the data analysis.
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